Supercharged immune cells take on tough lymphoma after transplant
NCT ID NCT02051257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new approach for patients with aggressive B-cell lymphoma that has come back after treatment. Researchers take a patient's own immune cells (T cells), modify them in the lab to better recognize and kill lymphoma cells, and give them back after a standard stem cell transplant. The goal is to find the highest safe dose and see if these enhanced cells can lower the chance of the cancer returning. About 51 people with high-risk lymphoma are participating.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Combination therapy aims to outsmart tough lymphoma
- New combo approach aims to boost CAR-T success in tough lymphoma
- New drug duo takes on tough lymphoma